This approach has advantages: the resulting model is immunocompetent and can be bred, and specific knowledge of restriction factors is not required. The resistance of mice to HCV is multifactorial and at least is determined by blocks in viral entry and

replication (Fig. 1A).7, 8 HCV entry is a complex process facilitated by four essential membrane proteins: scavenger receptor MAPK Inhibitor Library research buy class B type 1 (SCARB1), which is also known as SR-BI; CD81; claudin 1 (CLDN1); and OCLN.7, 11-13 Comparisons of the human and mouse orthologues reveal that, although mouse SCARB1 and mouse CLDN1 support HCV entry similarly to their human homologues, mouse CD81 (mCD81) and mouse OCLN do not (Fig. 1B).7 In their recent work, Bitzegeio et al.14 make an important first step toward developing a murine tropic virus. Using an unbiased selection approach, the authors

adapted a laboratory strain of HCV allowing to use HM781-36B supplier a mouse entry factor. Taking advantage of the high mutational plasticity of HCV, Bitzegeio et al. identified three adaptive mutations in viral glycoproteins E1 and E2 that allowed the virus to enter cells expressing human SCARB1, human CLDN1, human OCLN, and mCD81. Interestingly, both mutations in E2 are located in hypervariable region 1, which is thought to be dispensable for CD81 binding. These mutations strikingly increased the affinity of the virus for the large extracellular loop of hCD81, and this suggested an indirect enhancement by the exposure of a CD81 binding site. Moreover, the mCD81-adapted virus permitted entry via rat and hamster orthologues. In addition to modifying CD81 tropism, the adaptive mutations altered the usage of human SCARB1 and human OCLN. Blocking antibodies against human SCARB1 and silencing of human OCLN had a less pronounced effect on the entry of the mutant virus versus the parental strain, and this suggested that the mCD81-adapted virus was less dependent on SCARB1 and OCLN. In addition, mouse

fibroblasts expressing all four murine entry factors supported the uptake of adapted virus, and this entry could be blocked with anti-mCD81 antibodies; this Rucaparib supplier indicated that the species restriction to human OCLN was altered, whereas CD81 dependence was maintained. Structural changes in the murine-adapted E1/E2 complex were evident because affinities for neutralizing antibodies targeting conformational epitopes were drastically altered. Increased fusogenic activity of the mutant E1/E2 complex indicated that the adapted proteins might adopt a structure resembling that acquired during receptor interactions. It has previously been demonstrated that HCV requires not only a low pH shift but also additional primers for efficient membrane fusion.15 The latter requirement appears to be less stringent in the adapted glycoprotein complex, as measured by temperature shift assays.